INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Open market or private sale of non-derivative or derivative security | 10,000 | $20.05 | 9,647 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,000 | -- | -- |
| May 17, 2021 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Open market or private sale of non-derivative or derivative security | 10,336 | $519.47 | 28,086 |
| Jun 21, 2017 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 10,493 | $510.02 | 32,256 |
| Jul 24, 2009 |
SVP Res and Dev Sciences
|
SVP Res and Dev Sciences | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,537 | $9.49 | 10,887 |
| Jul 24, 2009 |
SVP Res and Dev Sciences
|
SVP Res and Dev Sciences | Form 4 | Open market or private sale of non-derivative or derivative security | 10,537 | $20.00 | 350 |
| Jul 24, 2009 |
SVP Res and Dev Sciences
|
SVP Res and Dev Sciences | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,537 | -- | -- |
| Dec 15, 2004 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,537 | -- | 10,537 |
| Jun 14, 2017 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 10,822 | $475.56 | 32,517 |
| Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 10,843 | $16.40 | 16,284 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.